CoQ10 in Huntington’s study
This article was originally published in The Tan Sheet
The effect of coenzyme Q10 on cognitive function in Huntington's disease patients will be tested in a phase III clinical trial by the Huntington Study Group, according to a June 2 release. The five-year study will measure the maximum effective dosage of CoQ10 for treating Huntington's, a genetic, progressive brain disorder with no known cure or proven drug therapy. Pasadena, Texas-based Kaneka Nutrients will supply the supplement for the trial. In addition to its documented neurological benefits, CoQ10 has cardio health advantages pharmaceutical developers are attempting to harness (1"The Tan Sheet" June 2, 2008, p. 8)...
You may also be interested in...
Dwindling product pipelines are pushing pharmaceutical companies to look to dietary supplements for business opportunities, not only through product sales but also by using herbal substances to develop new drug ingredients
AstraZeneca has sent a legal notice to Indian partner Serum Institute for non-delivery of its COVID-19 vaccine. Could this and a refund to the South African government dent Serum’s fortunes? Will the EMA and MHRA announcement on clotting incidents related to the AZ vaccine shrink demand?
As medical organizations such as the Veterans Health Administration and Mayo Clinic are positioning themselves to become medical device manufacturers using 3D printing technologies, it opens challenges and opportunities. See what Mayo Clinic’s Sean McEligot said about it here.